Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares

Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics (ELVN) at a weighted average price of $22.408 on September 16, 2024, according to a Form 4 filing.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc. (ELVN), sold 1,270 shares of common stock on September 16, 2024.
• The sale was executed at a weighted average price of $22.408, with individual prices ranging from $22.11 to $22.715.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 17, 2023.
• Following the transaction, Heyman directly owns 129,103 shares.
• He also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 27,918 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan, reducing the impact of the sale as a signal of management's view on the company's prospects.

Industry Context

Insider sales are a common occurrence and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects; however, sales under 10b5-1 plans are less indicative of management sentiment.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the context of Heyman's overall holdings and compensation structure.
• Generally, insider sales are compared to historical trading patterns of the individual and similar transactions by insiders at peer companies.
• Companies like Amgen, Gilead, and Regeneron are examples of large biotech firms where insider trading activity is closely monitored.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates